Baxter International Inc BAX

$ICU I can't believe the broader market is sleeping on this. Saves half of the people who would otherwise die from sepsis due to cytokine storm. Billions in TAM, about to roll out not just for kids but soon for adults in 2027 and no one realizes the import. 6 Breakthrough Device Designations ranging from Kidney, to Cardio, to Respiratory. Unreal we got in on the ground floor. $IBRX $JNJ $MRK $BAX

$ICU Vantive($BAX): The SCD fits easily, as does Vantive, as our International, upfront $10,000,0000.00 PREMIUM paying partner with the SCD-PED. The 20%-25% royalties after device cost reimbursement plus the 10%-15%, for incidentals. International royalties will become a reality in 3-18 months. which is the necessary timeframe for the required foreign government medical organization’s approvals. That’s a lot of JACK. SeaStar and $FMS will handle US sales, training and distribution of the Adult device, next summer. SeaStar will ramp up new hires for the training, sales and distribution of the pediatric device here in the USA after the CMS billing codes become active late this week. The SAVE Registry will become unrequired in the coming 2-4 weeks, even sooner, hopefully. 4th qtr. revenues should be quite impressive. -Prismaflex machine, a staple of the Vantive acute therapy portfolio, serves as the primary pump and fluid management platform for this configuration: Physical Mounting: When pairing the devices, an SCD securing bracket must be physically affixed to the right side of the Prismaflex control unit using pre-attached adhesive strips or zip-ties. Tubing Connections: The specialized SCD blood tubing set connects directly in series with the standard Vantive Prismaflex hemofilter tubing sets (such as the HF20, HF1000, or HF1400). Target Indication & MechanismPatient Population: The therapy is indicated for critically ill pediatric patients weighing 10 kg or more (up to 22 years of age) suffering from acute kidney injury (AKI) due to sepsis or septic conditions. Immunomodulatory Role: While the Vantive Prismaflex manages fluid balance and metabolic clearance, the SCD-PED acts as a disease-modifying immunomodulator. It works within the extracorporeal circuit to target, desensitize, and deactivate over-activated neutrophils and monocytes, helping to halt the hyperinflammatory cascade ("cytokine storm") that causes organ damage.Clinical & Operational PrerequisitesRegional Citrate Anticoagulation (RCA): The SCD-PED mechanism relies strictly on a low-calcium environment to selectively bind hyper-inflammatory white blood cells. Clinicians must use regional citrate anticoagulation protocols on the Prismaflex system to maintain a circuit ionized calcium (iCa²⁺) level below 0.40 mmol/L.Standard Vantive Disposables: The protocol requires standard Prismaflex components, zero-calcium bicarbonate solution, and accessory connectors for calcium and citrate infusions to manage the anticoagulation loop effectively.

$ICU An easy International no brainer partnership for $BAX : Children and parents rejoice! It may already be a done deal simply awaiting on the FDA’s official pronouncement concerning the eradication of the SAVE Registry. Next week? In two weeks? This Monday? Next Wednesday? Right before All Hallows Eve? “The integration of the SCD-PED (Selective Cytopheretic Device for Pediatrics / QUELIMMUNE) with Vantive (formerly Baxter Kidney Care) systems represents a specialized pairing for pediatric critical care. Core System Integration & PairingThe SCD-PED cartridge is designed specifically as an integrated adjunct to an existing continuous kidney replacement therapy (CKRT) or continuous renal replacement therapy (CRRT) system. It cannot function as a standalone device. The Prismaflex machine, a staple of the Vantive acute therapy portfolio, serves as the primary pump and fluid management platform for this configuration:Physical Mounting: When pairing the devices, an SCD securing bracket must be physically affixed to the right side of the Prismaflex control unit using pre-attached adhesive strips or zip-ties.Tubing Connections: The specialized SCD blood tubing set connects directly in series with the standard Vantive Prismaflex hemofilter tubing sets (such as the HF20, HF1000, or HF1400). Target Indication & MechanismPatient Population: The therapy is indicated for critically ill pediatric patients weighing 10 kg or more (up to 22 years of age) suffering from acute kidney injury (AKI) due to sepsis or septic conditions.Immunomodulatory Role: While the Vantive Prismaflex manages fluid balance and metabolic clearance, the SCD-PED acts as a disease-modifying immunomodulator. It works within the extracorporeal circuit to target, desensitize, and deactivate over-activated neutrophils and monocytes, helping to halt the hyperinflammatory cascade ("cytokine storm") that causes organ damage.Clinical & Operational PrerequisitesRegional Citrate Anticoagulation (RCA): The SCD-PED mechanism relies strictly on a low-calcium environment to selectively bind hyper-inflammatory white blood cells. Clinicians must use regional citrate anticoagulation protocols on the Prismaflex system to maintain a circuit ionized calcium (iCa²⁺) level below 0.40 mmol/L. Standard Vantive Disposables: The protocol requires standard Prismaflex components, zero-calcium bicarbonate solution, and accessory connectors for calcium and citrate infusions to manage the anticoagulation loop effectively.” Yeahhhhh..

$BAX Buyers stepping in today 👀

$BAX I work at the old Hillrom that Baxter bought for give or take $12B. Our market cap is less than $12B now. I wonder sometimes why one of the real big boys don’t buy Baxter. It’s like buying Hillrom for $12B and get the rest for free. We have been in a hole for 4 + years. We make it to $30 for a day or 2 then right back down. Baxter has had zero influence on Hillrom. The business is being ran the exact same way as when Hillrom was in charge it. Something has got to change. Baxter at the time of purchase was $80, Hillrom $156. Don’t hate me, I am a small fry, but a Baxter investor.

$BAX Looking to buy - 21.90?

$BAX juicy.

$ICU $BAX The Swiss need next to no government approval time to import a medicine. I am not sure about the Austrians, but as the two are paired in this Baxter presentation, it very well could be the case. Vantive is Baxter’s nephrological spin off. It occurred last summer. Why? The Quelimmune SCD-PED’s coming to the European/Asian/South American/Central American/ Arabian/ African/ Canadian/Australian/ New Zealand/Mid-Eastern/Indian critical care facilities after these American CMS codes take effect in 3 weeks and the required SAVE Registry for the pediatric device disappears on, or about the same date in the world’s medical history book!!! The time is running short to maximize your share count. Don’t be left out in the cold. Be bold. Be smart. Be a millionaire in 2030. Be a multimillionaire in 2035. Be a winner!!!!! This Holy Grail is only going to pass you by in the next week to 6 weeks if you do not act and act decisively ahora mismo. Comprehended? Muy bien!